摘要
卡维地洛是非选择性兼具有血管扩张作用的 β受体阻滞剂 ,并有抗氧化特性。大规模临床试验结果显示可改善心衰患者的预后 ,而成为第一个被美国FDA批准用于治疗心衰的 β受体阻滞剂。
Carvedilol is nonselective β receptor blocker with vasodilative and antioxidative properties.The results of large scale,randomized placebo controlled clinical trials have shown that carvedilol can improve the prognosis of patients with heart failure.It had been approved to treat congestive heart failure by FDA.This paper summarized the advances in clinical application and pharmacology of carvedilol for treatment of congestive heart failure.
出处
《现代诊断与治疗》
CAS
2002年第2期99-101,共3页
Modern Diagnosis and Treatment
